Literature DB >> 21757044

Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease.

Lin T Guey1, Clive R Pullinger, Brian Y Ishida, Patricia M O'Connor, Christian Zellner, Omar L Francone, Jason M Laramie, Josefina M Naya-Vigne, Ketevan A Siradze, Prakash Deedwania, Rita F Redberg, Philip H Frost, Albert B Seymour, John P Kane, Mary J Malloy.   

Abstract

Preβ-1 high-density lipoprotein (HDL) plays a key role in reverse cholesterol transport by promoting cholesterol efflux. Our aims were (1) to test previous associations between preβ-1 HDL and coronary heart disease (CHD) and (2) to investigate whether preβ-1 HDL levels also are associated with risk of myocardial infarction (MI). Plasma preβ-1 HDL was measured by an ultrafiltration-isotope dilution technique in 1,255 subjects recruited from the University of California-San Francisco Lipid and Cardiovascular Clinics and collaborating cardiologists. Preβ-1 HDL was significantly and positively associated with CHD and MI even after adjustment for established risk factors. Inclusion of preβ-1 HDL in a multivariable model for CHD led to a modest improvement in reclassification of subjects (net reclassification index 0.15, p = 0.01; integrated discrimination improvement 0.003, p = 0.2). In contrast, incorporation of preβ-1 HDL into a risk model of MI alone significantly improved reclassification of subjects (net reclassification index 0.21, p = 0.008; integrated discrimination improvement 0.01, p = 0.02), suggesting that preβ-1 HDL has more discriminatory power for MI than for CHD in our study population. In conclusion, these results confirm previous associations between preβ-1 HDL and CHD in a large well-characterized clinical cohort. Also, this is the first study in which preβ-1 HDL was identified as a novel and independent predictor of MI above and beyond traditional CHD risk factors.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757044     DOI: 10.1016/j.amjcard.2011.03.054

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

Review 1.  Time to ditch HDL-C as a measure of HDL function?

Authors:  Graziella E Ronsein; Jay W Heinecke
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

Review 2.  Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL.

Authors:  Patrick M Hutchins; Jay W Heinecke
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

3.  Importance of evaluating cell cholesterol influx with efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosis.

Authors:  Ginny L Weibel; Denise Drazul-Schrader; Debra K Shivers; Alisha N Wade; George H Rothblat; Muredach P Reilly; Margarita de la Llera-Moya
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-11-07       Impact factor: 8.311

4.  HDL efflux capacity, HDL particle size, and high-risk carotid atherosclerosis in a cohort of asymptomatic older adults: the Chicago Healthy Aging Study.

Authors:  R Kannan Mutharasan; C Shad Thaxton; Jarett Berry; Martha L Daviglus; Chun Yuan; Jie Sun; Colby Ayers; Donald M Lloyd-Jones; John T Wilkins
Journal:  J Lipid Res       Date:  2017-01-03       Impact factor: 5.922

5.  Influence of HDL particles on cell-cholesterol efflux under various pathological conditions.

Authors:  Bela F Asztalos; Katalin V Horvath; Michael Mehan; Yuya Yokota; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2017-04-18       Impact factor: 5.922

6.  Short-term physical inactivity impairs vascular function.

Authors:  Emily V Nosova; Priscilla Yen; Karen C Chong; Hugh F Alley; Eveline O Stock; Alex Quinn; Jason Hellmann; Michael S Conte; Christopher D Owens; Matthew Spite; S Marlene Grenon
Journal:  J Surg Res       Date:  2014-02-12       Impact factor: 2.192

7.  Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function.

Authors:  Angel C Y Mak; Clive R Pullinger; Ling Fung Tang; Jinny S Wong; Rahul C Deo; Jean-Marc Schwarz; Alejandro Gugliucci; Irina Movsesyan; Brian Y Ishida; Catherine Chu; Annie Poon; Phillip Kim; Eveline O Stock; Ernst J Schaefer; Bela F Asztalos; Joseph M Castellano; Tony Wyss-Coray; Jacque L Duncan; Bruce L Miller; John P Kane; Pui-Yan Kwok; Mary J Malloy
Journal:  JAMA Neurol       Date:  2014-10       Impact factor: 18.302

Review 8.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

9.  Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks.

Authors:  Xin-Min Li; Wai Hong Wilson Tang; Marian K Mosior; Ying Huang; Yuping Wu; William Matter; Vivian Gao; David Schmitt; Joseph A Didonato; Edward A Fisher; Jonathan D Smith; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-21       Impact factor: 8.311

Review 10.  From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.

Authors:  Frank M Sacks; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.